Methicillin-resistant Staphylococcus Aureus Drugs Market Size & Share, by Drug Class (Lipopeptide, Oxazolidine, Tetracycline, Cephalosporin, Lipoglycopeptide, Folate Antagonist); Administration (Oral, Parenteral); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5531
  • Published Date: Jan 15, 2024
  • Report Format: PDF, PPT

Companies Dominating the Methicillin-resistant Staphylococcus Aureus Drugs Landscape

    • BD (Becton, Dickinson and Company)
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Melinta Therapeutics LLC
    • Dr. Reddy’s Laboratories Ltd.
    • Cardinal Health
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Baxter
    • Crown Laboratories, Inc.
    • Atlantic Biologicals
    • Apollo Health Care Corporation Inc. 

Browse Key Market Insights with Data Illustration:


In The News

  • Leading international medical technology company BD (Becton, Dickinson and Company) announced receiving FDA 510(k) clearance for its new BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application. The application leverages artificial intelligence (AI) to interpret bacterial growth and release negative specimens with minimal human intervention.
  • Melinta Therapeutics (Melinta) is a commercial-stage company that develops novel treatments for acute and life-threatening illnesses. The company recently announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that treats acute bacterial skin and skin structure infections (ABSSSI) completely with a single 1,200 mg infusion that takes one hour. On March 12, 2021, the U.S. Food and Drug Administration approved KIMYRSA for the treatment of adult patients with ABSSSI brought on by susceptible isolates of specific Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).   

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5531
  • Published Date: Jan 15, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in geriatric population, rising adoption of AI in healthcare, and rise in product approval.

The market size of methicillin-resistant staphylococcus aureus drugs is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2024 – 2036.

The major players in the market are BD (Becton, Dickinson and Company), Melinta Therapeutics LLC, Dr. Reddy’s Laboratories Ltd., Cardinal Health, and others.

The hospital pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying